榴莲视频

Is "therapeutic inertia" to blame?

Starting monoclonal antibody therapy during childhood reduced long-term disability

Liver toxicity may still be a concern

Patients with high NfL at disease onset may benefit from high-efficacy treatments

Analysis looks at pooled data of 17,000 MS trial participants

Ozanimod led to test score improvements in interim analysis

Subgroup analysis shows brain penetration

NfL changes occurred in advance of, not coincident with, clinical worsening

MS field faces immense opportunity to move beyond disease suppression, keynote speaker says

Both provided rapid B-cell depletion

CD40 ligand inhibitor leads to sustained reduction of MRI disease activity

DELIVER-MS shows racial and ethnic diversity in clinical trials can be improved

Rituximab did not show non-inferiority in comparative effectiveness study

ARISE trial investigates radiologically isolated syndrome